Avi Kapoor
Compass Therapeutics
CMPX · NASDAQ
$0.8333−$0.0017 (−0.20%)TodayMarket closed ·
Prev close $0.835
About CMPX
- Employees
- 39
- Headquarters
- Boston, Massachusetts
- Listed
- Nov 13, 2020
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- compasstherapeutics.com
CMPX key statistics
- Market cap
- 150.07M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 7.21M
- Volume
- 1.88M
- Open price
- $0.8331
- High today
- $0.8679
- Low today
- $0.8221
- 52 Week high
- $6.88
- 52 Week low
- $0.8217
Compass Therapeutics (CMPX) at a glance
As of Oct 20, 2026, Compass Therapeutics (CMPX) shares are priced at $0.8333, giving the company a market cap of 150.07M and a price-to-earnings ratio of 0.00.
Today the stock has traded between $0.8221 and $0.8679. The current price is 1.4% above the day's low and 4.0% below its high.
Volume so far is 1.88M shares, below the average of 7.21M shares a day.
Over the past year Compass Therapeutics has ranged from $0.8217 to $6.88, and now sits 0% of the way up that range.
Compass Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1105.
The average analyst price target is $6.03, 623.3% above the current price, from 11 recent ratings.
Analyst ratings
Latest rating from each analyst over the past 12 months
91%of 11 analyst ratings say Buy
- Buy90.9%
- Hold9.1%
- Sell0.0%
Price target · 13 analystsAvg $6.03
- Low
- $1.01
- Now
- $0.8333
- High
- $12.60
CMPX earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 4 of the last 8 quarters, by 19.1% on average.
- Q3 FY24: reported -$0.08 per share against an estimate of -$0.1156
- Q4 FY24: reported -$0.11 per share against an estimate of -$0.1001
- Q1 FY25: reported -$0.12 per share against an estimate of -$0.1132
- Q2 FY25: reported -$0.14 per share against an estimate of -$0.1247
- Q3 FY25: reported -$0.08 per share against an estimate of -$0.1403
- Q4 FY25: reported -$0.09 per share against an estimate of -$0.0922
- Q1 FY26: reported -$0.10 per share against an estimate of -$0.1001
- Q2 FY26: reported -$0.13 per share against an estimate of -$0.1105
CMPX news
- Vandana Singh
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
- Avi Kapoor
Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
- Press releaseGlobe Newswire
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
- Press releasePRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Press releaseGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Similar companies
Companies in the same industry as Compass Therapeutics
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.